Literature DB >> 15466443

Impairment of the low-affinity state beta1-adrenoceptor-induced relaxation in spontaneously hypertensive rats.

Mohamed Yassine Mallem1, Gilles Toumaniantz, Sabrina Serpillon, Freddy Gautier, Marc Gogny, Jean-Claude Desfontis, Chantal Gauthier.   

Abstract

1 In hypertension, a decrease of the vascular beta-adrenergic relaxation has been described. However, the specific involvement of each beta-adrenoceptor (beta-AR) subtype, in particular the low-affinity state of beta1-AR, has not yet been evaluated. We investigated whether the low-affinity state of beta1-AR-induced relaxation was impaired in Spontaneously Hypertensive Rats (SHR). 2 The relaxant responses to CGP 12177 and cyanopindolol, low-affinity state beta1-AR agonists (with beta1-/beta2-AR antagonistic and partial beta3-AR agonistic properties) were evaluated on thoracic aortic rings isolated from 12-weeks-old Wistar Kyoto rats (WKY) and SHR. 3 In WKY, CGP 12177 and cyanopindolol produced an endothelium and nitric oxide (NO)-independent relaxation. CGP 12177-induced endothelium-independent relaxation was not modified either by beta1-, beta2-AR (nadolol) or beta3-AR (L-748337 or SR 59230A) antagonists but was significantly reduced by high concentrations of CGP 20712A (P<0.05). This relaxation was also reduced by adenylyl cyclase inhibitors, SQ 22536 or MDL 12330A. 4 In SHR, CGP 12177 produced mainly an endothelium and NO-dependent relaxation. This effect was not modified by nadolol, but was strongly reduced by beta3-AR blockade. Endothelium-independent relaxation to CGP 12177 was not altered by adenylyl cyclase inhibition, but was amplified in preparations from pertussis toxin-pretreated SHR. 5 The immunohistochemical analysis revealed an upregulation of beta3-AR in the endothelial layer of SHR aorta, whereas the beta3-AR-induced relaxation was not modified. 6 In conclusion, we demonstrated an impaired low-affinity state of the beta1-AR-induced relaxation and an upregulation of the beta3-AR in hypertension. Some clinical implications of those findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466443      PMCID: PMC1575435          DOI: 10.1038/sj.bjp.0705990

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Desensitization and resensitization of beta 1- and putative beta 4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure.

Authors:  A R Kompa; R J Summers
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  Role of endothelium/nitric oxide in atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta.

Authors:  L Brawley; A M Shaw; A MacDonald
Journal:  Eur J Pharmacol       Date:  2000-06-16       Impact factor: 4.432

Review 3.  The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor.

Authors:  J G Granneman
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-02       Impact factor: 4.310

4.  Beta 1-, beta 2- and atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta.

Authors:  L Brawley; A M Shaw; A MacDonald
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  Relaxation of rat aorta by adenosine in diabetes with and without hypertension: role of endothelium.

Authors:  M Fahim; T Hussain; S J Mustafa
Journal:  Eur J Pharmacol       Date:  2001-01-19       Impact factor: 4.432

6.  Abolition of (-)-CGP 12177-evoked cardiostimulation in double beta1/beta2-adrenoceptor knockout mice. Obligatory role of beta1-adrenoceptors for putative beta4-adrenoceptor pharmacology.

Authors:  A J Kaumann; S Engelhardt; L Hein; P Molenaar; M Lohse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-01       Impact factor: 3.000

Review 7.  Vascular beta-adrenoceptor function in hypertension and in ageing.

Authors:  E S Werstiuk; R M Lee
Journal:  Can J Physiol Pharmacol       Date:  2000-06       Impact factor: 2.273

8.  Aryloxypropanolamine and catecholamine ligand interactions with the beta(1)-adrenergic receptor: evidence for interaction with distinct conformations of beta(1)-adrenergic receptors.

Authors:  A A Konkar; Z Zhu; J G Granneman
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

9.  Effects of monosodium glutamate-induced obesity in spontaneously hypertensive rats vs. Wistar Kyoto rats: serum leptin and blood flow to brown adipose tissue.

Authors:  M Iwase; K Ichikawa; K Tashiro; K Iino; N Shinohara; S Ibayashi; M Yoshinari; M Fujishima
Journal:  Hypertens Res       Date:  2000-09       Impact factor: 3.872

Review 10.  Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics.

Authors:  Noboru Toda
Journal:  Pharmacol Ther       Date:  2003-12       Impact factor: 12.310

View more
  12 in total

Review 1.  Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies.

Authors:  Chantal Gauthier; Bertrand Rozec; Boris Manoury; Jean-Luc Balligand
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  Do low-affinity states of beta-adrenoceptors have roles in physiology and medicine?

Authors:  Jonathan R S Arch
Journal:  Br J Pharmacol       Date:  2004-11       Impact factor: 8.739

3.  Beta adrenergic modulation of spontaneous microcontractions and electrical field-stimulated contractions in isolated strips of rat urinary bladder from normal animals and animals with partial bladder outflow obstruction.

Authors:  J I Gillespie; C Rouget; S Palea; C Granato; C Korstanje
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-06-07       Impact factor: 3.000

Review 4.  Tools to study beta3-adrenoceptors.

Authors:  Wim Vrydag; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-01-09       Impact factor: 3.000

5.  Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor.

Authors:  Jillian G Baker; Richard G W Proudman; Stephen J Hill
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

Review 6.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.

Authors:  An L Moens; Ronghua Yang; Vabren L Watts; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2010-02-23       Impact factor: 5.000

7.  Different β-adrenoceptor subtypes coupling to cAMP or NO/cGMP pathways: implications in the relaxant response of rat conductance and resistance vessels.

Authors:  N Flacco; V Segura; M Perez-Aso; S Estrada; J F Seller; F Jiménez-Altayó; M A Noguera; P D'Ocon; E Vila; M D Ivorra
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

8.  Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta.

Authors:  Bertrand Rozec; Thuy Tran Quang; Jacques Noireaud; Chantal Gauthier
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

9.  Anti-hypertrophic and anti-oxidant effect of beta3-adrenergic stimulation in myocytes requires differential neuronal NOS phosphorylation.

Authors:  Vabren L Watts; Fernando M Sepulveda; Oscar H Cingolani; Alice S Ho; Xiaolin Niu; Rosa Kim; Karen L Miller; Koenraad Vandegaer; Djahida Bedja; Kathleen L Gabrielson; Gerald Rameau; Brian O'Rourke; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2013-05-02       Impact factor: 5.000

10.  The changes in beta-adrenoceptor-mediated cardiac function in experimental hypothyroidism: the possible contribution of cardiac beta3-adrenoceptors.

Authors:  E Arioglu; S Guner; I Ozakca; V M Altan; A T Ozcelikay
Journal:  Mol Cell Biochem       Date:  2009-09-01       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.